Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.
The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...
2d
Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions – – Reflects positive ...
The latest episode of the only podcast that focuses exclusively on crime in the Quad Cities has just dropped. Watch the video ...
Extends US patent protection until 2042MONTREAL and CHARLOTTE, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the ...
Joe Budden had some harsh criticism for 50 Cent following his reaction to the death of his longtime rival, Irv Gotti. Now, 50 ...
1d
The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/a3eb5opb. To listen to the conference call on your telephone, participants may ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...
Sickle cell disease is a severe, inherited blood disorder that primarily affects people of African, Mediterranean, Middle Eastern, and Indian descent.Despite its widespread impact, SCD research has ...
Welcome to Listening Habits, a new column where I share the music I’ve been fixated on recently. What is it like to make ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback